Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses
AbstractA successful anti-cancer vaccine construct depends on its ability to induce humoral and cellular immunity against a specific antigen. Targeting receptors of dendritic cells to promote the loading of cancer antigen through an antibody-mediated antigen uptake mechanism is a promising strategy in cancer immunotherapy. Researchers have been targeting different dendritic cell receptors such as Fc receptors (FcR), various C-type lectin-like receptors such as dendritic and thymic epithelial cell-205 (DEC-205), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), and Dectin-1 to enhance the uptake process and subsequent presentation of antigen to T cells through major histocompatibility complex (MHC) molecules. In this review, we compare different subtypes of dendritic cells, current knowledge on some important receptors of dendritic cells, and recent articles on targeting those receptors for anti-cancer immune responses in mouse models. View Full-Text
Share & Cite This Article
Hossain, M.K.; Wall, K.A. Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses. Cancers 2019, 11, 418.
Hossain MK, Wall KA. Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses. Cancers. 2019; 11(3):418.Chicago/Turabian Style
Hossain, Md K.; Wall, Katherine A. 2019. "Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses." Cancers 11, no. 3: 418.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.